Sort   by:  
 Page size 
ProteomicsProtein interactors of 5-FU in MDA-MB-231 cells
This dataset originates from a Proteome Integral Solubility Alteration (PISA) experiment designed to assess how 5-fluorouracil (5-FU) alters protein thermal stability/solubility in MDA-MB-231 cells. Cells were treated with 200 μM 5-FU or DMSO for 2 h, exposed to a temperature gradient, lysed, and so...
ORGANISM(S): Homo sapiens (Human) 
2026-02-16 | PXD072095 | Pride
5-fluorouracil Mda-mb-231 5-fu Pisa 
TranscriptomicsmiRNA profiling data of mouse bone marrow samples four days post 5-FU treatment versus untreated controls
To identify miRNAs that regulate hematopoietic response after 5-FU-induced injury, we analyzed miRNA expression changes in bone marrow cells from mice with or without 5-FU treatment. Global miRNA expression profiling of the 5-FU and untreated cohorts showed that 92 miRNAs (among 168 that passed the ...
ORGANISM(S): Mus musculus 
2012-09-24 | E-GEOD-39211 | biostudies-arrayexpress
TranscriptomicsComparative genomic hybridization of strains of Leishmania infantum wild-type and five independent 5-fluorouracil resistant mutant.
The genomic DNAs of strains 263 of L. infantum and five derived independent resistant mutants to 5-fluorouracil were used in comparative genomic hybridizations to reveal the deletion and/or amplification events occured by drug resistance mechanisms. The human protozoan parasites Leishmania are proto...
ORGANISM(S): Leishmania infantum 
2013-12-31 | E-GEOD-45866 | biostudies-arrayexpress
ProteomicsImpact of 5-FU on the proteome of HEK293T cells
In this study, we wanted to examine the effects of 5-fluorouracil, a drug used in anticancer treatment, on the proteome of HEK293T cells (human cell culture). HEK293T cells were exposed to 5-fluorouracil (5-FU) using two different incubation strategies. In the first experiment, cells were incubated ...
ORGANISM(S): Homo sapiens (Human) 
2025-03-18 | PXD051672 | Pride
Hek293t 5-fluorouracil Shotgun proteomics Human cell culture 
ClinicalModulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RAS-mutated mCRC patients
Interventions: Group 1: FOLFIRI or mFOLFIRI (q14d) + cetuximab (q7d): o Irinotecan 180 mg/m² iv, 30 - 90 min, day 1 o Folinic acid (racemic) 400 mg/m² iv, 120 min, day 1 o [5-FU 400 mg/m² bolus, day 1] o 5-FU 2400 mg/m² iv over 46 h, day 1-2 o Cetuximab initially 400 mg/m² as a 120 min infusion (= 5...
2437805 | ecrin-mdr-crc
UnknownGemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Not available
S-EPMC2788250 | biostudies-literature
UnknownMicrocurrent stimulation induces cell death in p53-mutant and 5-FU-resistant breast cancer.
Not available
S-EPMC12301737 | biostudies-literature
UnknownCardiorenal outcomes after herpes zoster reactivation in COVID-19 survivors from a global TriNetX study.
Not available
S-EPMC12357886 | biostudies-literature
UnknownDeterminants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial.
Not available
S-EPMC11995005 | biostudies-literature
ProteomicsReducing Dietary Protein Enhances the Anti-tumor Effects of Chemotherapy
Diet is believed to be an important mediator of oncogenesis and response to anti-cancer therapies, although, no evidence-based dietary guidelines exist for patients with cancer. Limiting protein intake can suppress tumor growth by both inducing nutrient stress and enhancing anti-tumor immunity. Howe...
ORGANISM(S): Mus musculus (Mouse) 
2025-03-07 | PXD052110 | Pride
Cancer Cgas-sting Diet Chemotherapy 5-fu 
Sort   by:  
 Page size